Last edition
News about "T cell engager "
Vir Biotechnology's VIR-5500 Receives FDA Fast Track Designation for Prostate Cancer
Vir Biotechnology and Astellas are advancing VIR-5500 for late-line metastatic castration-resistant prostate cancer following encouraging preliminary Phase 1 findings.
T-Cell Engager | 12/10/2026 | By News Bureau
GSK to Acquire Chimagen's Trispecific T-Cell Engager for Multiple Myeloma
GSK agrees to acquire global rights to Chimagen Biosciences’ investigational trispecific T-cell engager for multiple myeloma in a deal valued at up to USD 750 million.
T-cell Engager | 16/09/2026 | By News Bureau
Antengene Advances ATG-201 Autoimmune Programme with Australian Phase I Trial Approval
Antengene’s ATG-201 moves into multinational clinical development after receiving Australian ethics approval and completing the TGA’s CTN process for a Phase I study targeting B cell-related autoimmune diseases.
T-cell Engager | 26/08/2026 | By News Bureau | 105
AbbVie Reports Positive Phase 3 Results for Epcoritamab in Diffuse Large B-Cell Lymphoma
AbbVie reported positive phase 3 results for epcoritamab plus lenalidomide, showing improved Progression-Free Survival (PFS) in patients with relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL).
T-cell Engager | 01/07/2026 | By News Bureau | 137
IN8bio Prices Private Placement of up to USD 40.2 Million
IN8bio has priced a private placement of up to USD 40.2 million, comprising USD 20.1 million upfront and a milestone-based additional USD 20.1 million, to advance its novel gamma-delta T cell engager INB-619 towards an IND application, extend its cash runway into the first half of 2027.
T Cell Engager | 20/12/2025 | By News Bureau | 218
IN8bio Prices Private Placement of up to USD 40.2 Million
IN8bio has priced a private placement of up to USD 40.2 million, comprising USD 20.1 million upfront and a milestone-based additional USD 20.1 million, to advance its novel gamma-delta T cell engager INB-619 towards an IND application, extend its cash runway into the first half of 2027.
T Cell Engager | 20/12/2025 | By News Bureau | 218
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy